E74a Rapid Renewal Tissues: Colon and Rectum

Topic

The epithelium lining the colon completely renews itself in a very short time—between three and five days—because a very large proportion of its cells is constantly in the genetic material synthesis phase, the stage of the cell cycle where the cell duplicates its deoxyribonucleic acid prior to division.

This high proportion of actively dividing cells is precisely what makes the colon epithelium—and the tumors arising from it—particularly sensitive to chemotherapy; one of the most commonly used chemotherapy drugs for this type of tumor, 5-fluorouracil, acts specifically during that synthesis phase, making it more effective the greater the proportion of tumor cells undergoing division at any given time.

However, this rapid turnover and constant proliferation also have a negative consequence: they accelerate the accumulation of mutations within the colon epithelial cells, thereby speeding up the tumor's clonal evolution. This progressive accumulation of mutations follows a well-known pattern called the adenoma-carcinoma sequence—first described by researchers Eric Fearon and Bert Vogelstein—in which a benign colon polyp (an adenoma) accumulates successive mutations until it eventually transforms into an invasive carcinoma.

Venous blood from the colon drains directly into the liver via the portal vein, just as it does from the rest of the intestine; consequently, when a colorectal tumor spreads, there is a very high probability that the initial metastatic seeding will target the liver, following that same portal venous route. A subset of colorectal tumors also exhibits a specific defect in the mechanisms that repair errors occurring during the replication of genetic material—a defect known as microsatellite instability. This is particularly common in patients with Lynch syndrome, a hereditary condition that predisposes individuals to this type of tumor. When this repair defect is pronounced, the tumor accumulates an extraordinarily high total mutational burden—far exceeding that of most other colorectal tumors—making these tumors especially responsive to immunotherapies that block immune checkpoints (the same immune system "braking" mechanism targeted by checkpoint inhibitors).

It is this dual nature of rapid colonic epithelial turnover—high sensitivity to chemotherapy targeting dividing cells, yet also rapid mutation accumulation driving tumor evolution via the adenoma-carcinoma sequence—combined with the portal venous route that preferentially directs metastases to the liver and the potential for microsatellite instability (opening the door to immunotherapy), that makes colorectal cancer a particularly compelling case for personalized treatment tailored to each patient's physical and biological characteristics.

ID:4236